Skip to content

ENT FiberLase CO2 Study

ENT FiberLase CO2 Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01276418
Enrollment
49
Registered
2011-01-13
Start date
2010-10-31
Completion date
2012-03-31
Last updated
2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal Diseases, Pharyngeal Diseases

Brief summary

This study is intended to collect data regarding treatment with a new flexible fiber used to transmit laser emitted from a Carbon dioxide (CO2) laser to the transoral region. This study will include a single treatment that is performed transorally (through the mouth) for oral or laryngeal indications in the field of Ear, Nose and Throate (ENT).

Interventions

DEVICECO2 laser

Ablation and coagulation of soft tissue

Sponsors

Lumenis Be Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. General good health allowing patient to undergo general anaesthesia or heavy sedation according to the specific procedure. 2. Adult 3. Able and willing to comply with all visit, treatment and evaluation schedule and requirements 4. Able to understand and provide written Informed Consent 5. Disease which requires tissue ablation for treatment

Exclusion criteria

1. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to each treatment (as per the patient's physician discretion); 2. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Physician would interfere with the anesthesia, treatment, or healing process 3. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse; 4. Any condition which, in the Physician's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research

Design outcomes

Primary

MeasureTime frameDescription
Ability to complete procedure with the study deviceImmediate - during interventionThe number of interventions that were completed using the AcuPulse WG and FiberLase CO2 Fiber for the intended indication, without the need to revert to other means
Complications (bleeding, perforation, damage to non target tissue)During intervention and up to 6 weeks following the procedureNumber of subjects with Adverse Events as a Measure of Safety

Countries

Belgium, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026